BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. May 15, 2026; 18(5): 117580
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.117580
Figure 1
Figure 1 Study protocol. GAC: Gastric adenocarcinoma; OS: Overall survival; PGASC: Primary gastric adenosquamous carcinoma; PSM: Propensity score matching.
Figure 2
Figure 2 Overall survival in patients with gastric adenocarcinoma and primary gastric adenosquamous carcinoma. GAC: Gastric adenocarcinoma; PGASC: Primary gastric adenosquamous carcinoma.
Figure 3
Figure 3 Overall survival between patients with and without chemotherapy in the locally advanced gastric adenocarcinoma and the locally advanced primary gastric adenosquamous carcinoma groups. A: The gastric adenocarcinoma group after propensity score matching. Patients receiving adjuvant chemotherapy (blue line, n = 52) showed significantly better survival than those without (red line, n = 10) (log-rank test, P < 0.010); B: The primary gastric adenosquamous carcinoma group after propensity score matching. No significant difference was observed between the chemotherapy (blue line, n = 33) and non-chemotherapy (red line, n = 29) subgroups (time-dependent Cox regression, P = 0.810).


Write to the Help Desk